Partnering with Nonprofits to Make an Impact

AbbVie is contributing an additional $350 million to U.S.-based nonprofits this year. See how we’re partnering to serve students, families and communities in need.

Learn More

Our Journey of Impact

Come with us as we remember where we’ve been, and look forward to where we’re going.

Learn More

Latest News

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

Dec 13, 2018

AbbVie Announces $5 Billion Increase to Stock Repurchase Program

Dec 13, 2018

Inside our Design Lab: Building a Clinical Trial

Dec 05, 2018

Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE Study) Halted

Dec 04, 2018

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018
Read More

You must be logged in to view this item.

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?